Evaluation of EUCAST Rapid Antimicrobial Susceptibility Testing for Gram-Negative Bacteria Directly from Positive Blood Cultures

直接从阳性血培养物中评估 EUCAST 快速抗菌药物敏感性测试对革兰氏阴性菌的敏感性

阅读:1

Abstract

PURPOSE: This study aims to evaluate the accuracy of EUCAST rapid antimicrobial susceptibility testing (RAST) for Gram-negative bacteria directly from positive blood cultures, comparing it with short-term incubation (5-7 hours) and conventional broth microdilution methods. METHODS: A total of 139 Gram-negative isolates were tested. RAST results were assessed at 4 h, 6 h against minimal inhibitory concentration results using the short-term incubation (5-7 h) method, while at 16-20 h, the RAST results were compared to conventional method. For those with interpretable results, CLSI M52 was used to define cutoffs for equivalence in antimicrobial susceptibility testing. RESULTS: Among all isolates, 80.6% (112/139) were successfully interpreted based on EUCAST RAST breakpoints, including Escherichia coli (81), Klebsiella pneumoniae complex (17), Pseudomonas aeruginosa (10) and Acinetobacter baumannii (4). The overall category agreements for all tested antibiotics were 98.9%, 99.5%, and 99.7% at 4, 6, and 16-20 hours, respectively, for E. coli, and 100% for K. pneumoniae, P. aeruginosa, and A. baumannii. The area of technical uncertainty rate significantly decreased over time, from 9.1% at 4 hours to 3.1% at 16-20 hours (p < 0.05). The method effectively identified extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant bacteria, demonstrating performance comparable to the BD system. Additionally, results for other Enterobacterales could be interpreted using the RAST breakpoints for E. coli. The integration of RAST into routine workflows provides rapid and accurate results without incurring additional costs or labor. CONCLUSION: RAST is a reliable and cost-effective method for testing Gram-negative bacteria directly from blood cultures, significantly reducing turnaround time. Utilizing RAST at various reading times (6 hours and 16-20 hours) optimizes clinical workflows, enhances antimicrobial stewardship, and improves patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。